Inhibitors of lysine methyl transferase
First Claim
Patent Images
1. The compound which is5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-N-((1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4′
- -(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((7-fluoro-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,N-((6,7-Dimethoxy-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((6-methoxy-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((5-fluoro-1-methyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((5-fluoro-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,tert-Butyl 4-(5-(1-(sec-butyl)-3-methyl-4-(((1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)carbamoyl)-1H-indo-6-yl)pyridin-2-yl)piperazine-1-carboxylate,1-(sec-Butyl)-3-methyl-N-((1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide,N-((6,8-Difluoro-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((8-fluoro-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-N-((1-methyl-3-oxo-7-(trifluoromethyl)-2,3-dihydroisoquinolin-4-yl)methyl)-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((1-ethyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((1-ethyl-7-fluoro-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,N-((1,7-Dimethyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,2,2-Dimethyl-N-((1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-7-(6-(piperazin-1-yl)pyridin-3-yl)-2,3-dihydrobenzofuran-5-carboxamide, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases, utilizing the compounds of the invention.
1 Citation
2 Claims
-
1. The compound which is
5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-N-((1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4′ - -(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((7-fluoro-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,N-((6,7-Dimethoxy-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((6-methoxy-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((5-fluoro-1-methyl-3-oxo-1,2,3,4-tetrahydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((5-fluoro-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,tert-Butyl 4-(5-(1-(sec-butyl)-3-methyl-4-(((1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)carbamoyl)-1H-indo-6-yl)pyridin-2-yl)piperazine-1-carboxylate, 1-(sec-Butyl)-3-methyl-N-((1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide, N-((6,8-Difluoro-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((8-fluoro-1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-N-((1-methyl-3-oxo-7-(trifluoromethyl)-2,3-dihydroisoquinolin-4-yl)methyl)-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((1-ethyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((1-ethyl-7-fluoro-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,N-((1,7-Dimethyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′
-(morpholinomethyl)-[1,1′
-biphenyl]-3-carboxamide,2,2-Dimethyl-N-((1-methyl-3-oxo-2,3-dihydroisoquinolin-4-yl)methyl)-7-(6-(piperazin-1-yl)pyridin-3-yl)-2,3-dihydrobenzofuran-5-carboxamide, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. - View Dependent Claims (2)
- -(morpholinomethyl)-[1,1′
Specification